Coya Therapeutics, Inc. (COYA)

Coya Therapeutics' stock price has been influenced by several events. In November 2025, the company reported third-quarter financial results and received $4.2 million from Dr. Reddy's Laboratories. In January 2026, Coya announced an $11.1 million private placement. In March 2026, Coya reported fiscal year 2025 financial results, with increased collaboration revenue but a widened net loss, and announced the launch of the ALSTARS Phase 2 trial for COYA 302 in ALS and FDA acceptance of an IND application for COYA 302 for FTD. In April 2026, the company announced the publication of data supporting COYA 302 in ALS, leading to a stock increase, and a planned board transition. As of May 8, 2026, the stock price had fallen, and analysts gave Coya a consensus rating of 'Moderate Buy' with a $16.00 target price.

Coya Therapeutics, as a clinical-stage biotechnology company, does not experience traditional demand seasonality for its products and services. Its revenue is primarily derived from collaboration agreements and milestone payments, rather than sales of commercialized products.

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments that enhance regulatory T cell function to address systemic and neuroinflammation. The company's therapeutic approach targets neurodegenerative, autoimmune, and metabolic diseases. Coya's pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Major investigational products include COYA 302, a biologic combination therapy in Phase 2 trials for ALS and being developed for FTD, Alzheimer's, and Parkinson's; and COYA 303, a biologic combination being developed for inflammatory diseases. Other preclinical product candidates include COYA 301, COYA 201, COYA 206, and COYA 101.

Coya Therapeutics is headquartered in Houston, Texas. Clinical trials for COYA 302 in ALS are enrolling patients across approximately 25 clinical sites in the U.S. and Canada.

Coya Therapeutics' reputation is built on its scientific advancements, clinical trial progress, and potential to develop treatments for serious diseases. The company has engaged in scientific research and communication, with positive developments such as FDA acceptance of IND applications and the initiation of Phase 2 clinical trials contributing positively to its standing.

Coya Therapeutics has a mixed ownership structure with approximately 39.75% of the stock held by institutions, 12.00% by insiders, and 83.24% by retail investors. Major institutional owners include DME Capital Management, LP, AIGH Capital Management LLC, and Vanguard Group Inc. Notable individual owners include Howard Berman and Orin Hirschman.